SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a sharp intraday reversal, prompting discussions about potential market manipulation and the strength of the AI sector following Nvidia's earnings; traders are actively debating whether this pullback represents a buying opportunity or the start of a deeper correction, with some pointing to possible Yen carry trade issues.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing high volatility as traders debate whether recent drops signal a larger market correction or just a temporary pullback, fueled by concerns around AI valuations and potential recession indicators. Community sentiment is mixed, with some anticipating a bounce while others brace for further declines, closely watching key support levels and VIX movements. The conversation includes speculation about the Fed's next moves and the impact of economic data on market direction.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Despite strong earnings, NVIDIA is trending down, sparking debate about an AI bubble. The community is actively discussing whether the drop is a market correction, profit-taking, or manipulation by institutional investors. Some also point to comments from a Fed official raising concerns about valuations as a contributing factor.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending following a strong Q3 earnings report that included raised FY26 guidance and a surge in e-commerce sales, with discussion around its potential move to the Nasdaq. Community talking points include whether Walmart is a safe haven during market volatility and the impact of potential government shutdowns on SNAP benefits and consumer spending at Walmart stores.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a significant downturn, sparking debates about its role as a store of value and potential for further decline. Community discussions revolve around possible bottom levels, with some anticipating a substantial bounce while others fear a continued slide. The broader market context, including potential impacts from macroeconomic factors and liquidations, is also fueling uncertainty and volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending following a target price increase from UBS and rising memory prices linked to AI data-center demand, fueling discussions about its growth potential. Community members are weighing the bullish outlook against concerns of an overbought condition after the stock's significant year-to-date gains. Discussions also focus on potential short-term pullbacks versus long-term opportunities in the semiconductor space.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MELI is experiencing a significant downturn, with discussions focusing on a recent shelf filing and potential competition from Amazon as possible catalysts. The community is expressing concerns about the stock's performance, with some seeing the dip as a buying opportunity while others are wary of further declines. Broader macroeconomic factors and regional risks in Latin America are also being considered as contributing factors to the volatility.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending due to Bitcoin's price volatility, sparking debates on whether to buy the dip or brace for further declines; some community members point to potential manipulation and significant ETF outflows as bearish signals, while others highlight oversold conditions and historical patterns as reasons for optimism, with key options levels around \$50 also in focus.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to discussions around warrant redemptions and their impact on stock dilution, with a deadline approaching soon. The community is debating the company's long-term potential, its management, and comparing it to other rare earth companies, with some expressing concerns about recent performance and others highlighting its strategic partnerships and focus on heavy rare earth elements. News around the company's deal with Solvay and Saudi Arabian Mining Company (Maaden), meant to develop a rare earth refinery, has brought some recent attention.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as it hits fresh 52-week lows, with the community debating whether it's a buying opportunity or if further downside is expected due to its correlation with Bitcoin. Despite the recent price drop, some traders are noting unusual call option activity, suggesting contrarian bullish bets, while others point to potential liquidation levels and debt concerns.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Structure Therapeutics (NASDAQ:GPCR) Shares Up 6.6% - Here's What Happened

Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 6.6% - What's Next...

Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.7% - Here's What Happened

Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.7% - Time to Sell...

Leerink Partnrs Has Pessimistic View of GPCR FY2025 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Stock analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Structure Therapeutics in a...

Structure Therapeutics Inc. Sponsored ADR $GPCR Holdings Boosted by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC raised its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 90.9% in the second quarter, according to the company in its most recent...

Structure Therapeutics (NASDAQ:GPCR) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus...

NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?

Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.

Analysts delivered mixed verdicts on Eli Lilly after the drugmaker released late-stage trial results for its investigational oral weight-loss drug Orforglipron, sending shares sharply lower on Thursday.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly shares</a> closed down 14.1% at $640.86 on Thursday,&nbsp;their worst session since Aug. 9, 2000,&nbsp;but climbed in after-hours trading. The stock is now at lows last seen in early 2024.Leerink downgraded Eli Lilly to ‘Market Perform’ from ‘Outperform’ and cut its price target to $715 from $944, calling the results “disappointing” and lowering its long-term projections.&nbsp;The firm stated that its investment thesis had&nbsp;shifted and no longer&nbsp;anticipated upward pressure on consensus estimates, warning of rising GLP-1 competition by the end of the decade, even as rival Novo Nordisk faces pricing pressure.BofA, by contrast, called Eli Lilly’s second quarter (Q2) earnings and FY25 guidance raise “refreshing” compared with Novo’s “troubled” quarter, saying the drop in Lilly’s stock was “way overdone” and created a buying opportunity.&nbsp;The bank kept its ‘Buy’ rating and $1,000 price target, saying Eli Lilly remains “in pole position in obesity.”The Phase 3 ATTAIN-1 trial in 3,127 adults with obesity or overweight showed patients on the highest 36 mg dose l<a href="https://stocktwits.com/news-articles/markets/equity/nifty-sensex-recover-to-end-in-green-august-7/chrmRMkRddF">ost an average of 12.4% of body weight</a>, or 27.3 pounds, at 72 weeks, with nearly 60% losing at least 10%.&nbsp;Lilly stated that safety was consistent with injectable GLP-1 drugs, such as Mounjaro. The company plans to seek regulatory approval by the end of the year.H.C. Wainwright’s Joseph Pantginis said Viking Therapeutics’ VK2735 “remains a standout” after comparing discontinuation rates favorably with Eli Lilly’s data. The firm reiterated its ‘Buy’ rating on Viking with a $102 target and raised its target for Structure Therapeutics to $75 from $60, citing the potential of its oral GLP-1 candidate aleniglipron.Eli Lilly also lifted its 2025 revenue guidance midpoint by $1.5 billion to $60 billion–$62 billion and now expects adjusted EPS of $21.75–$23.The company’s Q2 revenue jumped 38% to $15.56 billion, with $5.2 billion from Mounjaro and $3.38 billion from Zepbound. Adjusted EPS was $6.31, topping forecasts.On Stocktwits, retail sentiment for Eli Lilly, which was among the top three trending tickers, was ‘extremely bullish’ amid a 1,228% surge in 24-message volume.One user on Stocktwits said they believed Eli Lilly shares would rebound eventually, but not immediately, noting that with Friday approaching and the rest of the world yet to react, it might be better to wait before adding more calls or shares.<stembedurl>https://stocktwits.com/SIbilisWhisper/message/624244609</stembedurl>Another user commented that they had bought as much stock as they could, calling it “way oversold” despite what they viewed as an extremely bullish earnings report, adding that stock market makers “are a mystery.”<stembedurl>https://stocktwits.com/Mypointofbay/message/624237111</stembedurl>Eli Lilly’s stock has declined&nbsp;about 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the highest dose resulting in an average weight loss of 27.3 pounds over 72 weeks.

Equity

Pfizer Inc.'s (PFE) decision to halt the development of its oral GLP-1 candidate due to a potential liver toxicity issue could pose tailwinds for smaller biotech rivals, according to Wall Street analysts.According to The Fly, JPMorgan thinks Pfizer's scrapping of its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ends-development-of-weight-loss-pill-danuglipron/chfCPelRba2">danuglipron</a> program opens the door for Structure Therapeutics’ (GPCR)GSBR-1290 (aleniglipron) to become the second small molecule oral GLP-1 to reach the market.It also makes Viking Therapeutics' (VKTX) an "even more attractive partnership candidate," the analyst said.Meanwhile, BTIG also flagged Viking as a key beneficiary, reiterating its 'Buy' rating and $125 price target, implying a 400% upside from the last close.&nbsp;The research firm pointed to Viking's "competitive" oral candidate VK2735, currently in Phase 2 trials, with data expected in the second half of 2025.&nbsp;A Phase 3 study for the injectable form is also set to begin in the second quarter.Media reports suggest Pfizer could now look to external assets. BTIG said it remains focused on Viking's "compelling pipeline and data" regardless of Pfizer's next steps.Retail sentiment for Viking Therapeutics turned 'bullish' late Monday from 'bearish' a day ago, accompanied by an 8,220% surge in message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/VKTX_sentiment_and_message_volume_on_April_14_png_16bef741c1.webp" alt="VKTX sentiment and message volume on April 14.png" width="1318" height="316"><figcaption>VKTX sentiment and message volume on April 14. | source: Stocktwits</figcaption></figure>One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."<stembedurl>https://stocktwits.com/rxptgh/message/611544179</stembedurl>Another watcher speculated that Pfizer could likely buy Viking Therapeutics following the news.<stembedurl>https://stocktwits.com/KnysnaNow/message/611596706</stembedurl>Structure Therapeutics, meanwhile, saw its sentiment meter jump into 'extremely bullish' levels from 'bearish' a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/GPCR_sentiment_and_message_volume_on_April_14_png_6c34839d3e.webp" alt="GPCR sentiment and message volume on April 14.png" width="1318" height="316"><figcaption>GPCR sentiment and message volume on April 14. | source: Stocktwits</figcaption></figure>A bullish user said the company's aleniglipron "is going to be best in class" among GLP-1 oral pills, and CEO Ray Stevens "knows it's an easy winner and big money."<stembedurl>https://stocktwits.com/DAR2487/message/611630051</stembedurl>Structure's stock is down over 30% year to date, while Viking's has lost nearly 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

 Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For Viking, Structure Therapeutics

Structure CEO on the competitive landscape for oral GLP-1 drugs

Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings...

Promising Outlook for Structure Therapeutics with Strong Pipeline and Financial Stability

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR Research Report) today and s...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.39	--	--	N/A
Q3 '25	-$0.38	-$0.37	1.40%	BEAT
Q2 '25	-$0.34	-$0.36	-5.04%	MISSED
Q1 '25	-$0.26	--	--	N/A
Q4 '24	-$0.21	--	--	N/A

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest GPCR News

GPCRStructure Therapeutics Inc - ADR